Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy

Introduction

Posttraumatic stress disorder (PTSD) is a chronic and often debilitating condition defined by re-experiencing, avoidance, hyperarousal, and negative mood/cognition changes. Epidemiological estimates cited by the authors put lifetime prevalence in the general population at 6.8%, with substantially higher rates reported among Iraq and Afghanistan veterans. Existing treatments have important limitations: only two drugs (sertraline and paroxetine) are approved, many psychotherapies incur high dropout, and prolonged exposure (PE) therapy—while evidence-based—can be intolerable or inaccessible to many patients. The authors note mechanistic and practical barriers to current treatments, including impaired therapeutic alliance, a narrow therapeutic window for arousal, and avoidance that drives attrition in exposure-based approaches. Against this background, the paper considers MDMA-assisted psychotherapy (MDMA-AP) as an emerging option. MDMA is described as a psychotherapeutic adjunct that may reduce anxiety, increase trust and insight, and widen the “therapeutic threshold,” potentially improving engagement with trauma-focused work. Two clinical MDMA-AP trials had been published at the time. Amoroso and Workman set out to produce a preliminary meta-analysis of those MDMA-AP trials and to compare their cumulative effect sizes and dropout rates with those reported in an existing meta-analysis of PE, arguing that effect size (rather than p-values alone) is a useful comparative metric when sample sizes differ widely.